AC Immune SA宣布，其研发的抗阿尔法-突触核蛋白主动免疫疗法ACI-7104，已获得美国食品药品监督管理局（FDA）授予的快速通道资格。这一疗法旨在针对早期帕金森病（Pd）进行治疗。快速通道资格的获批，有望加速该药物从研发到临床应用的进程，为患者带来更早的干预可能。
AC Immune SA宣布，其研发的抗阿尔法-突触核蛋白主动免疫疗法ACI-7104，已获得美国食品药品监督管理局（FDA）授予的快速通道资格。这一疗法旨在针对早期帕金森病（Pd）进行治疗。快速通道资格的获批，有望加速该药物从研发到临床应用的进程，为患者带来更早的干预可能。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.